These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

445 related items for PubMed ID: 31395860

  • 21. ProNGF siRNA inhibits cell proliferation and invasion of pancreatic cancer cells and promotes anoikis.
    Xu J, Song J, Yang X, Guo J, Wang T, Zhuo W.
    Biomed Pharmacother; 2019 Mar; 111():1066-1073. PubMed ID: 30841420
    [Abstract] [Full Text] [Related]

  • 22. CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing.
    Shen P, Yang T, Chen Q, Yuan H, Wu P, Cai B, Meng L, Huang X, Liu J, Zhang Y, Hu W, Miao Y, Lu Z, Jiang K.
    Mol Cancer; 2021 Mar 09; 20(1):51. PubMed ID: 33750389
    [Abstract] [Full Text] [Related]

  • 23. Downregulated miR-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4.
    Fu Y, Liu X, Chen Q, Liu T, Lu C, Yu J, Miao Y, Wei J.
    J Exp Clin Cancer Res; 2018 Jul 03; 37(1):130. PubMed ID: 29970191
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Tumor-derived exosomal lnc-Sox2ot promotes EMT and stemness by acting as a ceRNA in pancreatic ductal adenocarcinoma.
    Li Z, Jiang P, Li J, Peng M, Zhao X, Zhang X, Chen K, Zhang Y, Liu H, Gan L, Bi H, Zhen P, Zhu J, Li X.
    Oncogene; 2018 Jul 03; 37(28):3822-3838. PubMed ID: 29643475
    [Abstract] [Full Text] [Related]

  • 27. The Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer.
    Guo K, Cui J, Quan M, Xie D, Jia Z, Wei D, Wang L, Gao Y, Ma Q, Xie K.
    Clin Cancer Res; 2017 Feb 01; 23(3):687-696. PubMed ID: 27449499
    [Abstract] [Full Text] [Related]

  • 28. A novel prognostic factor TIPE2 inhibits cell proliferation and promotes apoptosis in pancreatic ductal adenocarcinoma (PDAC).
    Sun Y, Cao S, Li Z, Liu X, Xu J, Tian Y, Shen S, Zhou Y.
    Int J Med Sci; 2021 Feb 01; 18(9):2051-2062. PubMed ID: 33850476
    [Abstract] [Full Text] [Related]

  • 29. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
    Okada Y, Takahashi N, Takayama T, Goel A.
    Carcinogenesis; 2021 Apr 30; 42(4):546-556. PubMed ID: 33624791
    [Abstract] [Full Text] [Related]

  • 30. Epigenetics of epithelial-to-mesenchymal transition in pancreatic carcinoma.
    Träger MM, Dhayat SA.
    Int J Cancer; 2017 Jul 01; 141(1):24-32. PubMed ID: 28133736
    [Abstract] [Full Text] [Related]

  • 31. Silencing of LAMC2 Reverses Epithelial Mesenchymal Transition and Inhibits Progression in Pancreatic Ductal Adenocarcinoma via Inactivation of the NF-κB Signaling Pathway.
    Huang L, Han Y, Zhou Q, Sun Z, Yan J.
    Crit Rev Eukaryot Gene Expr; 2023 Jul 01; 33(4):13-23. PubMed ID: 37183943
    [Abstract] [Full Text] [Related]

  • 32. Small Nucleolar Noncoding RNA SNORA23, Up-Regulated in Human Pancreatic Ductal Adenocarcinoma, Regulates Expression of Spectrin Repeat-Containing Nuclear Envelope 2 to Promote Growth and Metastasis of Xenograft Tumors in Mice.
    Cui L, Nakano K, Obchoei S, Setoguchi K, Matsumoto M, Yamamoto T, Obika S, Shimada K, Hiraoka N.
    Gastroenterology; 2017 Jul 01; 153(1):292-306.e2. PubMed ID: 28390868
    [Abstract] [Full Text] [Related]

  • 33. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1.
    Chen H, Li L, Hu J, Zhao Z, Ji L, Cheng C, Zhang G, Zhang T, Li Y, Chen H, Pan S, Sun B.
    J Exp Clin Cancer Res; 2019 Jul 09; 38(1):297. PubMed ID: 31288830
    [Abstract] [Full Text] [Related]

  • 34. High expression of AFAP1-AS1 is associated with poor survival and short-term recurrence in pancreatic ductal adenocarcinoma.
    Ye Y, Chen J, Zhou Y, Fu Z, Zhou Q, Wang Y, Gao W, Zheng S, Zhao X, Chen T, Chen R.
    J Transl Med; 2015 Apr 30; 13():137. PubMed ID: 25925763
    [Abstract] [Full Text] [Related]

  • 35. Epigenetic reprogramming-induced guanidinoacetic acid synthesis promotes pancreatic cancer metastasis and transcription-activating histone modifications.
    Yang J, Ren B, Ren J, Yang G, Fang Y, Wang X, Zhou F, You L, Zhao Y.
    J Exp Clin Cancer Res; 2023 Jun 28; 42(1):155. PubMed ID: 37370109
    [Abstract] [Full Text] [Related]

  • 36. Integrin β6 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC).
    Li Z, Lin P, Gao C, Peng C, Liu S, Gao H, Wang B, Wang J, Niu J, Niu W.
    Tumour Biol; 2016 Apr 28; 37(4):5117-31. PubMed ID: 26547582
    [Abstract] [Full Text] [Related]

  • 37. Citron Rho-Interacting Serine/Threonine Kinase Promotes HIF1a-CypA Signaling and Growth of Human Pancreatic Adenocarcinoma.
    Cong L, Bai Z, Du Y, Cheng Y.
    Biomed Res Int; 2020 Apr 28; 2020():9210891. PubMed ID: 32185224
    [Abstract] [Full Text] [Related]

  • 38. SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells.
    Li S, Hong H, Lv H, Wu G, Wang Z.
    Med Sci Monit; 2016 May 12; 22():1593-600. PubMed ID: 27170223
    [Abstract] [Full Text] [Related]

  • 39. LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K/Akt signaling pathway.
    Zhang H, Pan YZ, Cheung M, Cao M, Yu C, Chen L, Zhan L, He ZW, Sun CY.
    Cell Death Dis; 2019 Mar 08; 10(3):230. PubMed ID: 30850586
    [Abstract] [Full Text] [Related]

  • 40. MicroRNA‑766 inhibits the malignant biological behaviours of pancreatic ductal adenocarcinoma by directly targeting ETS1.
    Li S, Yan G, Yue M, Kang Z, Wang L.
    Mol Med Rep; 2019 Feb 08; 19(2):1380-1387. PubMed ID: 30569091
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.